

References

Y-5001

1. Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). *J Cancer Res Clin Oncol*. Feb 2011;137(2):305-310. PMID 20407789.
2. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. *Nat Rev Cancer*. Apr 2008;8(4):299-308. PMID 18354418.
3. Tang X, Liu T, Zang X, et al. Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. *PLoS One*. May 2013;8(5):e62847. PMID 23667530.
4. Xie F, Zhang X, Li H, et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. *PLoS One*. Aug 2012;7(8):e42879. PMID 22916174.
5. Zhong JH, Ma L, Wu LC, et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. *Int J Clin Pract*. Jan 2012;66(1):21-27. PMID 22171902.
6. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. *J Clin Oncol*. Mar 10 2014;32(8):798-808. PMID 24344220.
7. Chia WK, Teo M, Wang WW, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. *Mol Ther*. Jan 2014;22(1):132-139. PMID 24297049.
8. Ohtani T, Yamada Y, Furuhashi A, et al. Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers. *Int J Oncol*. Nov 2014;45(5):2051-2057. PMID 25120101.
9. Schuessler A, Smith C, Beagley L, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. *Cancer Res*. Jul 1 2014;74(13):3466-3476. PMID 24795429.

10. Li JJ, Gu MF, Pan K, et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. *J Immunother.* Feb-Mar 2012;35(2):189-195. PMID 22306907.
11. Liu L, Zhang W, Qi X, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. *Clin Cancer Res.* Mar 15 2012;18(6):1751-1759. PMID 22275504.
12. Zhang Y, Wang J, Wang Y, et al. Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. *Clin Dev Immunol.* Jan 2013;2013:195691. PMID 24382970.
13. Zhao X, Zhang Z, Li H, et al. Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. *Cancer Lett.* Jul 1 2015;362(2):192-198. PMID 25843292.
14. Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. *Cancer Immunol Immunother.* Dec 2012;61(12):2251-2259. PMID 22674056.
15. Wang X, Tang S, Cui X, et al. Cytokine-induced killer cell/dendritic cell-cytokine-induced killer cell immunotherapy for the postoperative treatment of gastric cancer: A systematic review and meta-analysis. *Medicine (Baltimore).* Sep 2018;97(36):e12230. PMID 30200148.
16. Zhao H, Wang Y, Yu J, et al. Autologous cytokine-induced killer cells improves overall survival of metastatic colorectal cancer patients: results from a phase II clinical trial. *Clin Colorectal Cancer.* Sep 2016;15(3):228-235. PMID 27052743.
17. Nazemalhosseini-Mojarad E, Mohammadpour S, Torshizi Esafahani A, et al. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features. *J Cell Physiol.* Oct 28 2018. PMID 30370522.
18. Cai XR, Li X, Lin JX, et al. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review. *Oncotarget.* May 09 2017;8(19):31318-31328. PMID 28412743.

19. Yu X, Zhao H, Liu L, et al. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. *J Clin Immunol*. Feb 2014;34(2):194-203. PMID 24337625.
20. Cui J, Wang N, Zhao H, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. *Int J Cancer*. Jan 15 2014;134(2):342-351. PMID 23825037.
21. Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. *Gastroenterology*. Jun 2015;148(7):1383-1391 e1386. PMID 25747273.
22. Wang M, Cao JX, Pan JH, et al. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer. *PLoS One*. Nov 2014;9(11):e112662. PMID 25412106.
23. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. *J Clin Oncol*. Nov 10 2008;26(32):5233-5239. PMID 18809613.
24. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin Cancer Res*. Jul 01 2011;17(13):4550-4557. PMID 21498393.
25. Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. *Cancer Immunol Immunother*. Nov 2002;51(10):539- 546. PMID 12384805.
26. Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. *J Clin Oncol*. Aug 1999;17(8):2521-2529. PMID 10561318.
27. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotypic-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. *Blood*. Mar 01 2002;99(5):1517-1526. PMID 11861263.
28. Lacy MQ, Wettstein P, Gastineau DA, et al. Dendritic cell-based idiotype vaccination in post transplant multiple myeloma [abstract]. *Blood*. 1999;94(10 supp part 1):122a.

29. Motta MR, Castellani S, Rizzi S, et al. Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. *Br J Haematol.* Apr 2003;121(2):240-250. PMID 12694245.
30. Triozzi PL, Khurram R, Aldrich WA, et al. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. *Cancer.* Dec 15 2000;89(12):2646-2654. PMID 11135227.
31. Bedrosian I, Mick R, Xu S, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. *J Clin Oncol.* Oct 15 2003;21(20):3826-3835. PMID 14551301.
32. Shi SB, Ma TH, Li CH, et al. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. *Tumori.* May-Jun 2012;98(3):314-319. PMID 22825506.
33. Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. *Cancer Immunol Immunother.* Jan 2013;62(1):65- 73. PMID 22744010.
34. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. *Cancer Res.* May 01 2003;63(9):2127-2133. PMID 12727829.
35. Santin AD, Bellone S, Palmieri M, et al. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. *Gynecol Oncol.* May 2003;89(2):271-280. PMID 12713991.
36. Tanyi JL, Chu CS. Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review. *Immunotherapy.* Oct 2012;4(10):995-1009. PMID 23148752.
37. Bregy A, Wong TM, Shah AH, et al. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. *Cancer Treat Rev.* Dec 2013;39(8):891-907. PMID 23790634.
38. Liao LM, Ashkan K, Tran DD, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. *J Transl Med.* May 29 2018;16(1):142. PMID 29843811.

39. Chen R, Deng X, Wu H, et al. Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis. *Int Immunopharmacol*. Oct 2014;22(2):451-464. PMID 25073120.
40. Bachleitner-Hofmann T, Friedl J, Hassler M, et al. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. *Oncol Rep*. Jun 2009;21(6):1585-1592. PMID 19424640.
41. Hirooka Y, Itoh A, Kawashima H, et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. *Pancreas*. Apr 2009;38(3):e69-74. PMID 19276867.
42. Ngo MC, Rooney CM, Howard JM, et al. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. *Hum Mol Genet*. Apr 15 2011;20(R1):R93-99. PMID 21415041.
43. Ochi T, Fujiwara H, Yasukawa M. Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer. *Expert Opin Biol Ther*. Jun 2011;11(6):699-713. PMID 21413911.
44. Humphries C. Adoptive cell therapy: Honing that killer instinct. *Nature*. Dec 19 2013;504(7480):S13-15. PMID 24352359.
45. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. *Blood*. Jul 16 2009;114(3):535-546. PMID 19451549.
46. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti- CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. *Blood*. Oct 01 2007;110(7):2620-2630. PMID 17507664.
47. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. *Blood*. Sep 15 2008;112(6):2261-2271. PMID 18509084.
48. Pinthus JH, Waks T, Malina V, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. *J Clin Invest*. Dec 2004;114(12):1774-1781. PMID 15599402.

49. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. *Nat Med*. Nov 2008;14(11):1264-1270. PMID 18978797.
50. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: bladder cancer. Version 4.2019.
http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed September 2, 2019.
51. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: central nervous system cancers. Version 1.2019.
http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed September 2, 2019.
52. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: head and neck cancers. Version 2.2019.
http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed September 2, 2019.
53. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Version 3.2019.
http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed September 2, 2019.
54. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: kidney cancer. Version 2.2020.
https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed September 2, 2019.
55. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma. Version 3.2019.
http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed September 2, 2019.
56. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: gastric cancer. Version 2.2019.
http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed September 2, 2019.
57. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: thyroid carcinoma. Version 1.2019.

http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed September 2, 2019.

58. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: cutaneous melanoma. Version 2.2019
https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed September 2, 2019.

59. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 7.2019.
http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed September 2, 2019.